Efficacy and safety of BT595 (10% human intravenous immunoglobulin) in adult patients with chronic immune thrombocytopenia

被引:2
|
作者
Demeter, Judit [1 ]
Hamed, Aryan [2 ]
Laszlo, Szerafin [3 ]
Suvajdzic, Nada [4 ]
Aigner, Silke [5 ]
Boerner, Birgit [5 ]
Staiger, Christiane [5 ]
机构
[1] Semmelweis Univ, Med Sch, Dept Hematol, Budapest, Hungary
[2] Petz Aladar Megyei Oktato Korhaz, Belgyogyaszat Hematol Osztaly 2, Gyor, Hungary
[3] Szabolcs Szatmar Bereg Megyei Korhazak & Egyet Ok, Josa Andras Oktatokorhaz, Haematol Osztaly, Nyiregyhaza, Hungary
[4] Clin Ctr Serbia, Clin Haematol, Belgrade, Serbia
[5] Biotest AG, Landsteinerstr 5, Dreieich, Germany
关键词
BT595; chronic immune thrombocytopenia; ITP; phase III trial; pivotal; PURPURA; STANDARDIZATION; MANAGEMENT; CHILDREN;
D O I
10.1111/tme.12943
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose This trial investigated the efficacy and safety of the new 10% human intravenous immunoglobulin (IVIg) BT595 (Yimmugo (R)). Methods Adult patients with chronic immune thrombocytopenia (ITP) received a total dose of 2 g/kg body weight (bw) IVIg either over 2 or 5 days. Results Response as defined by the European Medicines Agency (EMA) was achieved in 18 of 34 patients (52.9%) in the full analysis set (FAS), with a complete response in 11 patients (32.4%). The median time to response was 1.0 days (range 1-4); the median duration was 28.0 days. In a subgroup with a baseline platelet count < 20*10(9)/L evaluated according to FDA criteria, a platelet response >= 50*10(9)/L was achieved in 18 of 19 patients at day 8. No fatal case occured. One serious treatment-emergent adverse event (TEAE) (anaemia, not related) was reported (2.9%). The most frequent infusional adverse drug reaction (ADR) was headache, which was reported for 14.7% of all patients. All other infusional ADRs (pyrexia, [intravascular] haemolysis, skin reaction, tinnitus, and Coombs test positive) occurred in only one patient (2.9%). Premedication was administered only once. The 5-day schedule showed less side effects with similar efficacy. Conclusion The benefit-risk profile of BT595 is favourable.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 50 条
  • [31] Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies
    Kovaleva, Lidia
    Apte, Shashikant
    Damodar, Sharat
    Ramanan, Vijay
    Loriya, Svetlana
    Navarro-Puerto, Jordi
    Khojasteh, Ali
    IMMUNOTHERAPY, 2016, 8 (12) : 1371 - 1381
  • [32] Study on the efficacy and safety of IGIV3I grifols (human intravenous immunoglobulin) in patients diagnosed with chronic immune thrombocytopenic purpura.
    Julia, Antonio
    Kovaleva, Lidia
    Alberca, Ignacio
    Hernandez, Fernando
    Loria, Svetlana
    Sandoval, Virgilio
    Vidaller, Antonio
    Sierra, Jorge
    BLOOD, 2006, 108 (11) : 66B - 66B
  • [33] Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura
    Aledort, L. M.
    Salama, A.
    Kovaleva, L.
    Robak, T.
    Newland, A. C.
    Nugent, D. J.
    Brenner, B.
    Zenker, O.
    HEMATOLOGY, 2007, 12 (04) : 289 - 295
  • [34] Efficacy and safety of a new intravenous immunoglobulin in adult subjects with chronic idiopathic thrombocytopenic purpura.
    Leibl, H
    Varga, G
    Volkova, Z
    Gasztonyi, Z
    Hlusi, A
    Mayer, J
    Chojnowski, K
    Wolf, HH
    Sharkhawy, M
    Pavlova, BG
    Birthistle, K
    Engl, W
    Walter, S
    Ehrlich, HJ
    BLOOD, 2005, 106 (11) : 76B - 76B
  • [35] Efficacy and safety of the new intravenous immunoglobulin IGIV 10% in adults with chronic idiopathic thrombocytopenic purpura
    Varga, Gyula
    Volkova, Zuzana
    Leibl, H.
    Gasztonyi, Zoltan
    Hlusi, Antonin
    Mayer, Jiri
    Chojnowski, Krzysztof
    Wolf, Hans-Heinrich
    Sharkhawy, Marlies
    Pavlova, Borislava G.
    Birthistle, Karl
    Engl, Werner
    Walter, Simone
    Ehrlich, Hartmut J.
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2006, 33 (06) : 509 - 514
  • [36] LONG-TERM EFFICACY AND SAFETY OF THROMBOPOIETIN AGONISTS IN ADULT REFRACTORY CHRONIC IMMUNE THROMBOCYTOPENIA
    Kaliou, M.
    Gavriilaki, E.
    Papaioannou, G.
    Bousiou, Z.
    Iskas, M.
    Vadikoliou, C.
    Lalayanni, C.
    Athanasiadou, A.
    Saloum, R.
    Anagnostopoulos, A.
    HAEMATOLOGICA, 2017, 102 : 834 - 834
  • [37] Subcutaneous Immunoglobulin (SCIG) in Responders to Intravenous Therapy with Chronic Immune Thrombocytopenia (ITP)
    Iuliano, Francesco
    Iuliano, Eleonora
    Luci, Maria
    Perricelli, Alessia
    Pomillo, Angelo
    Abruzzese, Elisabetta
    BLOOD, 2014, 124 (21)
  • [38] Safety and efficacy of a new 10% liquid immunoglobulin preparation for intravenous use in pediatric patients
    Lozano Blasco, J.
    Martin Mateos, M.
    Giner Munoz, M.
    Piquert Gibert, M.
    Dominguez Sanchez, O.
    Alvaro Lozano, M.
    Plaza Martin, A.
    ALLERGY, 2010, 65 : 477 - 478
  • [39] Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma
    Schachter, Jacob
    Katz, Uriel
    Mahrer, Arie
    Barak, Dov
    Ben David, Liat Ziegel
    Nusbacher, Jacob
    Shoenfeld, Yehuda
    AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH, 2007, 1110 : 305 - 314
  • [40] Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia
    Teeling, JL
    Jansen-Hendriks, T
    Kuijpers, TW
    de Haas, M
    van de Winkel, JGJ
    Hack, CE
    Bleeker, WK
    BLOOD, 2001, 98 (04) : 1095 - 1099